Government's Direct Drug Discount Platform

TrumpRx has launched and is expanding quickly, adding 600+ generics through deals with Cost Plus Drugs, Amazon and GoodRx and another 160 drugs in June 2026, so the platform is plainly gaining scope. None of the articles show measurable price impact, adoption levels or market-share shifts away from PBMs and traditional distribution. The partnerships route sales through existing discount players rather than replacing them, and consumer-facing pieces still question the actual savings. Neither the disruption thesis nor the falsification criteria (minimal price impact, low adoption, unchanged distribution) is clearly demonstrated yet.